Synonyms: ABT-493 | ABT493 | Maviret® | Mavyret® (glecaprevir + pibrentasvir)
glecaprevir is an approved drug (EMA & FDA (2017))
Compound class:
Synthetic organic
Comment: Glecaprevir is an orally available anti-hepatitis C virus (HCV) drug. It is a direct-acting inhibitor of the HCV NS3/4A protease, and thereby targets viral RNA replication.
|
|
No information available. |
Summary of Clinical Use ![]() |
Glecaprevir is used in fixed-dose combination with the HCV NS5A inhibitor pibrentasvir. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01995071 | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) | Phase 2 Interventional | AbbVie | 1 |
External links ![]() |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |